ALNA stock: Allena Pharmaceuticals (ALNA NASDAQ) $0.075 intraday 20 Jan 2026: heavy volume

ALNA stock is trading at USD 0.075 intraday on 20 Jan 2026, and volume is surging, marking it among the most active names on the NASDAQ in the United States. The price is up 3.16% from the prior close of USD 0.0727, with a day range of USD 0.06 to USD 0.1459 and reported volume of 252,311,606 shares. Traders are watching Allena Pharmaceuticals, Inc. (ALNA NASDAQ) after mixed fundamental signals: negative EPS of -0.64 and a low price-to-book near 0.13, offset by a cash buffer and pipeline progress. We look at trading drivers, valuation, and short-term outlook

Intraday trading snapshot for ALNA stock

ALNA stock is showing heavy intraday activity on the NASDAQ in the United States. The stock opened at USD 0.0641, touched a day high of USD 0.1459 and a day low of USD 0.06, while the reported volume sits at 252,311,606 shares. The move reflects speculative interest and thin-cap volatility. Short-term traders should expect wide spreads and rapid price swings given the low share price and unpredictable liquidity.

Fundamental picture: ALNA Allena Pharmaceuticals, Inc. stock analysis

Allena Pharmaceuticals, Inc. (ALNA NASDAQ) operates in Biotechnology within the Healthcare sector. Recent key metrics show EPS -0.64 and PE -0.12, reflecting ongoing losses as the company advances clinical-stage assets. Cash per share is USD 0.92 and book value per share is USD 0.58, with a current ratio of 2.11, suggesting short-term funding coverage. Revenue per share is USD 0.00, consistent with a development-stage biotech still pre-commercial. These fundamentals explain the speculative nature of ALNA stock and elevated volatility.

Meyka AI grade and valuation for ALNA stock

Meyka AI rates ALNA with a score out of 100: 58.60 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Price-to-book is 0.13, enterprise value measures show negatives due to low market cap, and return metrics are negative. The grade signals caution: the company has cash runway advantages but lacks revenue and shows persistent operating losses.

Technical and trading risks for ALNA stock

Technically, ALNA stock faces high downside risk from low liquidity and extreme historical drawdowns (1Y change -81.39%, max change -99.25%). The stock has no reliable 50- or 200-day averages, which weakens trend analysis. Interest coverage is negative at -63.40, and free cash flow metrics are negative. Day traders should use tight risk controls; longer-term investors must weigh binary clinical outcomes and potential corporate actions that often move microcap biotechs.

Catalysts and news flow affecting ALNA stock

Key catalysts for Allena Pharmaceuticals include clinical-stage updates for lead candidate ALLN-346, regulatory milestones, and financing activity. Company filings, trial readouts, or purchase agreements could drive sudden moves. For ongoing market context see major outlets such as Reuters and CNBC. Investors should track pipeline news and capital raises as the primary levers for ALNA stock price action.

Sector context and peers for ALNA stock outlook

ALNA stock sits in the Biotechnology industry where sector momentum matters. Biotech indices and peer trial readouts often drive correlated moves. Compared with peers, Allena shows lower market capitalization and thinner liquidity, increasing idiosyncratic risk. Investors should compare ALNA’s cash runway and trial stage against similarly sized biotech tickers before sizing positions. For a quick company page and live metrics visit our Meyka ALNA page.

Final Thoughts

Key takeaways for ALNA stock: the intraday price of USD 0.075 on 20 Jan 2026 and heavy 252,311,606 share volume place Allena Pharmaceuticals among the most active NASDAQ listings today in the United States. Fundamentals show negative EPS (-0.64) and negative profitability, balanced by USD 0.92 cash per share and a current ratio of 2.11. Meyka AI’s forecast model projects a near-term target of USD 0.12, implying an upside of 60.00% versus the current price USD 0.075. Forecasts are model-based projections and not guarantees. Given the C+ grade and development-stage profile, traders should treat ALNA stock as speculative. Short-term traders can exploit intraday momentum, while longer-term investors need confirmation from clinical or financing milestones before increasing exposure. Meyka AI, an AI-powered market analysis platform, will monitor real-time signals and news flow to update forecasts and grading as events unfold.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.